Industry Program Sponsor

Asahi Kasei Pharma Corporation

1735 - 1835 GMT+9
Monday 30 August

Evening Symposium 6

The role of targeted therapies against interleukin-6 receptor in rheumatoid arthritis

Rheumatoid arthritis (RA) is developed and maintained by complicated network communications of various immune cells mediated by cytokines. Among those cytokines, interleukin (IL)-6 plays a crucial role in the pathogenesis of RA. We have reported that IL-6 is a useful biomarker of RA disease activity while tumor necrosis factor (TNF) is a prognostic marker of RA. Further, we have speculated the difference between anti-IL-6 (ligand) antibody and anti-IL-6 receptor antibody from the viewpoint of variations in their molecular expression levels among patients with RA. Sarilumab, the first fully-human and high-affinity anti-IL-6 receptor biological disease-modifying antirheumatic drug (DMARD), has demonstrated considerable efficacy in domestic and global clinical trials irrespective of the patient characteristics such as a concomitant use of conventional synthetic DMARDs or a prior use of anti-TNF and other biological DMARDs. The safety profiles of sarilumab are comparable to those of tocilizumab, a humanized anti-IL-6 receptor biological DMARD developed in Japan, without any novel concerns. We should take care of the development of infectious diseases during the treatment with sarilumab, although it is not associated with neutropenia. In this seminar, the clinical positioning and future perspectives of IL-6 receptor blockade will be discussed with introducing the results from our recent translational researches and several clinical trials.

Chair: Prof Akio Morinobu, Kyoto University Graduate School of Medicine, Japan

Asahi Kasei Pharma Corporation

Asahi Kasei Pharma discovers, develops, manufactures, and delivers prescription drugs in the fields of orthopedics, circulatory, urology, the immune system, and the central nervous system.

Pharmaceuticals from Asahi Kasei Pharma include Teribone™ for osteoporosis and Elcitonin™ Injection 20S for osteoporosis pain, the Recomodulin™ anticoagulant, each of which has a competitive position in its respective market.

Kevzara® is a human monoclonal antibody that blocks the action of interleukin-6 (IL-6) by binding to IL-6 receptors, for the indication of rheumatoid arthritis in patients who have had an inadequate response to conventional treatments.

Kevzara® is a registered trademark of Sanofi Biotechnology.

The product information is intended for general information purposes. The names, descriptions, and labeling of approved products are of Japan origin.

Product availability, names, indications, and presentations may vary from country to country.

Laila Girgis

St Vincent’s Hospital Sydney And University Of New South Wales

Australia

Autologous Haematopoietic Stem Cell Transplantation For Systemic Sclerosis Results In Improved Clinical Outcome Measures Including Survival

Dr Laila Girgis is the Head of the Rheumatology Department and Senior Staff Specialist at St Vincent’s Hospital, Sydney. She is a Senior Lecturer (Conjoint) at the University of New South Wales, in the St Vincent’s Clinical School. She is co-supervising a PhD at the St Vincent’s Centre for Applied Medical Research, and also conducts medical teaching and clinical research.

Ying Ying Leung

Singapore General Hospital/ Senior Consultant.
Duke-nus Medical School/ Associate Professor.

Singapore

New Grappa Recommendation

A/Prof. Ying Ying LEUNG is Associate Professor at Duke-NUS Medical School, and Senior Consultant of the department of Rheumatology & Immunology of Singapore General Hospital (SGH). She is currently the head of research in the department of Rheumatology and Immunology. Her research interests are in psoriatic arthritis and osteoarthritis, focusing in evaluation and development of measurement instrument and biomarkers.

A/Prof. Leung has been the Asian chair of the GRAPPA-OMERACT Outcome Measure working group, and serves in the education committee in the Group For Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). She led the peripheral arthritis domain working group in the GRAPPA recommendation update 2021.

Janssen Pharmaceutical KK & Mitsubishi Tanabe Pharma Corporation

At Janssen, we’re creating a future where disease is a thing of the past. We’re the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.

Janssen Asia Pacific is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

CSF

The Cytokine Signalling Forum (CSF) is an educational website developed under the auspices of the University of Glasgow and is dedicated to the dissemination of the latest developments in cytokine signalling. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of the science of cytokines and cytokine signalling, and its implications for clinical practice. Visit our website at www.cytokinesignalling.com or follow us on social media at links below

Contact

Asami Abe

Niigata Rheumatic Center, Department of Rheumatology

Japan

Ultrasonography in the patients with rheumatoid arthritis treated by biological agents and Janus kinase inhibitor, the corresponding synovial histological findings

1985 4-1991 3 Asahikawa medical college
1991 4 Asahikawa medical college, Department of Orthopaedic surgery
1991 4-1999 3 Hospitals in Hokkaido, Department of Orthopaedic surgery
1999 4-2003 4 Asahikawa medical college, graduate school
2003 9-2004 7 Mount Sinai medical School, Human genetics, Postdoctoral Researcher
2004 7-2005 5 University of British Columbia, School of Dentistry, Postdoctoral Researcher
2005 6-2005 9 Asahikawa medical college, Department of Orthopaedic surgery
2005 10-2006 10 Niigata Prefectural Senami Hospital, Department of Rheumatology
2006 11- Niigata Rheumatic Center, Department of Rheumatology

Ori Elkayam

Tel Aviv medical center

Israel

2019 Update of EULAR Recommendations for vaccinations in adult patients with autoimmune inflammatory RMDs

Professor Ori Elkayam is Head of the department of Rheumatology, at the Tel Aviv Medical Center. She has completed her studies of Medicine at the Tel Aviv University and her training in rheumatology at the Tel Aviv Medical Center.

She was the President of the Israeli Society of Rheumatology from 2011 to 2017 and has published more than 190 publications in leading journals of rheumatology.

Her main clinical fields of interest are vaccination in rheumatic diseases, spondyloarthritis and interventional rheumatology.

Prof. Elkayam is a leading researcher on the effect of vaccinations in autoimmune diseases, being the chair of the EULAR task aimed at formulating the EULAR recommendations for vaccination in auto-immune inflammatory diseases. She is one of the architect of the Israeli Registry of rheumatic patients treated with biologics.

David Karp

American College of Rheumatology

United States

Progress in Systemic Lupus Erythematosus

Dr. David Karp is Professor and Chief of the Rheumatic Diseases Division at the University of Texas Southwestern Medical Center in Dallas, TX, where he holds the Harold C. Simmons Chair in Arthritis Research and the Fredye Factor Chair in Rheumatoid Arthritis Research. Dr. Karp’s recent investigation has focused on markers that predict development of disease in people at risk for systemic lupus erythematosus.

Dr. Karp has published over 100 research articles on rheumatology and immunology. He has received support for his research from the National Institutes of Health, the Lupus Research Alliance, the Arthritis Foundation and industry. Dr. Karp was President of the Rheumatology Research Foundation and is now President of the American College of Rheumatology.

Kong Kok Ooi

Tan Tock Seng Hospital

Singapore

Ultrasound and its clinical use in Psoriatic arthritis

Adj A/Prof Kong is the Head of the Department of Rheumatology, Allergy and Immunology Tan Tock Seng Hospital, Singapore. He established the first rheumatology ultrasonography service in Singapore in 2003 and since then has trained many other Rheumatologists in using ultrasound imaging as an aid in clinical practice.

Isao Matsumoto

Division Of Rheumatology, University Of Tsukuba

Japan

Recent topics of pathogenesis and therapy in rheumatoid arthritis

2002-2005 Researcher, PRESTO, Japan Science and Technology agency (An additional post)
2008- Associate Professor, Division of Rheumatology, Department of Internal Medicine, University of Tsukuba
2018- Deputy Director, Intractable Disease Medical Center, University of Tsukuba
2020- Director, Division of Rheumatology, Department of Internal Medicine, University of Tsukuba

Honors
2011 Novartis Prize for Rheumatology
2017 Prize from Japan College of Rheumatology

LG Chem

LG Chem, the leading chemical company, has strengthened market dominance starting from the Basic Materials & Chemicals business to Energy Solution, IT and Electronic Materials and Life Science area.

Life Sciences Company focuses at four major healthcare services including pharmaceutical, vaccine, medical device and biopharmaceutical.

Based on its own fundamental technology, LG Chem expanded its pipeline to include biosimilars in order to improve patient access to highly effective biological products.

LG Chem will continue to improve the quality of life by providing innovative portfolio of medicines across the world.

Contact

Iain McInnes

University of Glasgow

United Kingdom

The immune response to COVID-19 vaccinations in patients with impaired immune systems: the OCTAVE study

Iain McInnes is Vice Principal and Head of College of Medical Veterinary and Life Sciences, and Versus Arthritis Professor of Rheumatology in the University of Glasgow, Glasgow, United Kingdom. He is Director of the Versus Arthritis Centre of Excellence for Inflammatory Arthritis, lead from Glasgow that includes Universities of Oxford, Newcastle and Birmingham. He is immediate past chairman of the Foreum (Foundation for European Rheumatology Research) Scientific Committee, leads the European Roadmap programme that is defining the research agenda for European rheumatology for the next decade and is currently President of the European League Against Rheumatism (EULAR), the leading trans-national society for rheumatology across Europe.

Under these auspices he is creating the first pan-European Rheumatology Research Centre planning to launch in 2021. His work is mainly focused upon the understanding of the pathogenesis of immune mediated inflammatory diseases and encompasses basic discovery immunology through phase 1 and proof of concept experimental medicine clinical trials to leadership of pivotal phase 3 trials in the area of immune biology. His laboratory group performed original discovery work leading to the therapeutic targeting of a several inflammatory cytokines. More recently he has focused on the biology of myeloid cells in the pathogenesis of a number of immune diseases.

He has published >400 peer-reviewed original and review articles with an h-index of >100. He is a Fellow of the Royal Society of Edinburgh and Fellow of the Academy of Medical Sciences. He was made CBE in 2019 by HM Queen Elizabeth II.

CC Mok

Tuen Mun Hospital

Hong Kong

APLAR consensus statements on the management of SLE

Chi-Chiu Mok is currently the chief of the Division of Rheumatology, Department of Medicine, Tuen Mun Hospital, Hong Kong. He is a consultant physician and honorary teaching professor of the University of Hong Kong and the Chinese University of Hong Kong.

An active researcher, Dr. Mok is the first author of more than 200 papers in a number of medical and Rheumatology journals that include the Annals of the Rheumatic Diseases, Nature Review Rheumatology, Arthritis and Rheumatology, Rheumatology (Oxford), and Arthritis Care & Research. His research interests include systemic lupus erythematosus, particularly lupus nephritis, and glucocorticoid induced osteoporosis. Dr. Mok is also the principal investigator of a number of phase II/III global trials investigating the safety and efficacy of novel biological agents in various rheumatic diseases.

Dr. Mok is currently the senior associate editor of the International Journal of Rheumatic Diseases and an editorial member of more than 10 medical journals that include the Journal of Rheumatology, Lupus, Current Rheumatology Review, Open Orthopedic Journal and Immunology and Immunogenetic Insights.

Dr. Mok is a Past President of the Hong Kong Society of Rheumatology. He is the founder editor of the Journal of Clinical Rheumatology and Immunology, the official publication of the Hong Kong Society of Rheumatology.

Eric Morand

Monash University

Australia

Interferon inhibition

Professor Eric Morand graduated from Medicine at Monash University, trained in clinical rheumatology in Australia and at the Royal National Hospital for Rheumatic Diseases, UK and took his PhD at Monash University. His laboratory research focusses on glucocorticoid-induced proteins in the immune system, and his clinical research on systemic lupus erythematosus.

He founded the Lupus Clinic at Monash Health, and the Asia Pacific Lupus Collaboration, now the largest longitudinal cohort of SLE patients ever assembled. He chaired the 2017 International Congress on SLE, and awards include the William E Paul Distinguished Innovator Award of the Lupus Research Alliance, New York, Dean’s Award for Research Excellence, and the Parr Prize of the Australian Rheumatology Association.

Sandra Navarra

University of Santo Tomas Hospital

Philippines

B-directed therapies

Prof. Sandra Navarra is head of Rheumatology at University of Santo Tomas Hospital, Manila, and active consultant in Rheumatology at St. Luke’s Medical Center, Quezon City, Philippines. She served as Secretary-General, head of Education Committee, and chaired the SLE special interest group of Asia Pacific League of Associations for Rheumatology (APLAR). She was past-president of Philippine Rheumatology Association and is currently CEO of Rheumatology Educational Trust Foundation Inc. (RETFI) which oversees the Applied Rheumatology Made Simple (ARMS), Lupus Inspired Advocacy (LUISA) and People Empowerment for Arthritis and Lupus (PEARL) programs. Prof Navarra is a member of the Lupus Academy Steering Board, and founding-executive board member of both Asia Pacific Lupus Collaboration (APLC) and Asian Lupus Nephritis Network (ALNN).

Kenji Oku

Hokkaido University Graduate School Of Medicine

Japan

Prevention of infective complications in SLE for the APLAR consensus statements

Kenji Oku is an associate professor of the Department of Rheumatology, Endocrinology and Nephrology at the Hokkaido University Graduate School of Medicine. His interests have focused on both basic science and clinical research in SLE and the antiphospholipid syndrome.

Most recently, as the member of the standing committee of the APLAR, he and his colleagues published the Consensus Statements on the Management of SLE.　Additionally, as fellow of Japan College of Rheumatology (JCR), he holds various senior level positions including the executive director of the standing committee of the Japanese clinical guidelines of SLE.

Yohei Seto

Department Of Rheumatology, Tokyo Women’s Medical University Yachiyo Medical Center

Japan

Ultrasound and its clinical use in Crystal induced arthritis

Dr Yohei Seto is an associate professor in Rheumatology Department, Tokyo Women’s Medical University Yachiyo Medical Center. He is a former member of Japan College of Rheumatology (JCR) Ultrasound Standardization Committee. He had also involved in organizing standardized ultrasonography educational courses on behalf of JCR, and in establishing 2020 Japanese practice guideline for rheumatoid arthritis on behalf of Japanese Ministry of Health, Labour and Welfare and 2018 Japanese guideline for gout and hyperuricemia on behalf of Japanese Society of Gout and Uric & Nucleic Acids.

Association of Women in Rheumatology

AWIR is a global organization with more than 11,000 touchpoints and 8 global chapters/partners worldwide. AWIR’s mission is to promote the science and practice of Rheumatology, foster the advancement and education of women in Rheumatology, and advocate access to the highest quality health care, and the management of patients with Rheumatic diseases.

Amita Aggarwal

Sanjay Gandhi Postgraduate Institute of Medical sciences Lucknow

India

Cytokine targeted therapy for Rheumatic diseases in children in India

Amita Aggarwal is a Professor and Head of Clinical Immunology and Rheumatology at the Sanjay Gandhi Postgraduate Institute, Lucknow, India. She completed her medical education at All India Institute of Medical Sciences, New Delhi. She subsequently trained in Clinical Immunology & Rheumatology at SGPGI, Lucknow, Later, she trained at Royal Melbourne Hospital, Melbourne, Center’s for disease control, Atlanta, USA and Oklahoma university hospital, Oklahoma, USA in Immunology & Rheumatology.

She is a clinician scientist, with major interest in Juvenile arthritis and SLE. She has setup a multi-institutional lupus network in India. In addition, she has taught a generation of physicians working in the field of rheumatology. In recognition of her work, she has been elected fellow of the Indian academy of Science, National academy of Science as well as National academy of Medical Sciences. She has also served as the President of Indian Rheumatology Association as well as editor of Indian Journal of Rheumatology.

Pfizer. Japan Inc

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes human biologic and small molecule medicines and vaccines, as well as many of the world’s best-known consumer products.

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as the world’s leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

Janssen, a division of Johnson & Johnson

Janssen Asia Pacific is one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Eli Lilly Japan K.K.

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work.

Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.

AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow.

We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio.

Bristol Myers Squibb K.K.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Gilead Sciences K.K.

Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need. Gilead’s Inflammation R&D team is focused on improving therapeutic options for the treatment of multiple inflammatory conditions through a comprehensive clinical trial program evaluating novel agents with the goal of advancing patient care.

Novartis Pharma K.K.

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. We consistently rank among the world’s top companies investing in research and development.

Cesas Medical

Sales Operation Area Management Support, Japan Commercial, Astellas Pharma Inc.

Boehringer Ingelheim

Making new and better medicines for humans and animals is at the heart of what we do. Our mission is to create breakthrough therapies that change lives. Since its founding in 1885, Boehringer Ingelheim is independent and family-owned. We have the freedom to pursue our long-term vision, looking ahead to identify the health challenges of the future and targeting those areas of need where we can do the most good.

As a world-leading, research-driven pharmaceutical company, more than 51,000 employees create value through innovation daily for our three business areas: Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. In 2019, Boehringer Ingelheim achieved net sales of

19 billion euros. Our significant investment of almost 3.5 billion euros in R&D drives innovation, enabling the next generation of medicines that save lives and improve quality of life.

We realize more scientific opportunities by embracing the power of partnership and diversity of experts across the life-science community. By working together, we accelerate the delivery of the next medical breakthrough that will transform the lives of patients now, and in generations to come.

More information about Boehringer Ingelheim can be found at www.boehringer-ingelheim.com or in our annual report: www.annualreport.boehringer-ingelheim.com.

Chugai Pharmaceutical Co., Ltd

Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies with strengths in biotechnology products. As an important member of the Roche Group, Chugai is actively involved in R&D activities in Japan and abroad. Specifically, Chugai is working to develop innovative products which may satisfy the unmet medical needs.

Daiichi Sankyo Co., Ltd.

Glaxosmithkline

We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

UCB Biopharma SRL

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines. Our ambition is to transform the lives of people living with severe diseases, with a focus in immunology and neurology.

Lai-shan Tam

The Chinese University Of Hong Kong

Hong Kong

Axial psoriatic arthritis- is it different from axial spondyloarthritis?

Lai-Shan Tam, MD, is Division Head and a Professor in the Division of Rheumatology within the Department of Medicine and Therapeutics at The Chinese University of Hong Kong. She has been serving as the Chairperson of the International Affair Committee of APLAR since 2012.

She was President of the Hong Kong Society of Rheumatology from 2011 to 2014, and Vice President of APLAR from 2014-2016. In addition, Professor Tam was a member of the International Task Force Subcommittee of ACR, the EULAR Programme Committee from 2016-2019, and EULAR honorary member (since 2019). She serves as the Associate Editor of International Journal of Rheumatic Disease, and also as members of the editorial boards in a number of journals including Rheumatology, Frontiers in Medicine and the Latin American Journal of Psoriasis and Psoriatic Arthritis, and she is also the international advisory board member of the Lancet Rheumatology.

She is the first author or co-author of over 200 articles published in major rheumatology journals. Her research interests include premature atherosclerosis and bone loss in patients with rheumatic diseases.

Yannick Allanore

Paris Descartes University

France

Is disease modification possible?

Yannick Allanore is Professor of Rheumatology at the Paris Descartes University in Paris since 2008. Professor ALLANORE is the Head of a research group working on the cardio-pulmonary aspects of systemic sclerosis and other chronic inflammatory rheumatic diseases through clinical research programs and basic research ones, including genetic and cellular biology approaches, and also an animal model platform covering various models of inflammatory driven fibrosis (INSERM U1016, Cochin Institute).

He has published over 430 papers in peer-review journals. Professor Allanore is a member of several professional bodies, including the French Rheumatology Society and the American College of Rheumatology. He is the former elected chairman (2013-2019) of the The EUROPEAN Scleroderma Trials and Research group (EUSTAR). He is member of the Steering Committee of the World Scleroderma FOUNDATION, he was the chairman of the programme of the 2020 world scleroderma congress.

Keishi Fujio

University of Tokyo

Japan

Integrated functional genome analysis of immune-mediated diseases

1995 M.D. Medical School, University of Tokyo

1998-2000 Department of Hematopoietic Factors, Institute of Medical Science, Graduate
School of Medicine, University of Tokyo

2000-2002 Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo

2001-2002 Postdoctral Fellowship of Japan Society for Promotion of Science

2002-2005 Research Resident of Japan Association for Preventive Medicine

2006- 2013 Assistant Professor, Department of Allergy and Rheumatology,
Graduate School of Medicine, University of Tokyo

2013- Lecturer and Deputy Director, the Department of Allergy and Rheumatology, University of Tokyo Hospital

2017- Professor and Director, the Department of Allergy and Rheumatology, University of Tokyo Hospital

Katsuya Suzuki

Keio University

Japan

Molecular Understanding Of Remission In Rheumatoid Arthritis: A Concept Of Molecular Remission

Dr. Katsuya Suzuki is a rheumatologist, Assistant Professor of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University in Tokyo, Japan. He is also a councilor of Japan College of Rheumatology and The Japan Society for Clinical Immunology. His major research interests are pathogenesis, translational research and clinical studies/trials for autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, vasculitis, Sjogren’s syndrome, and IgG4-related syndrome.

Ran Nakashima

Kyoto University Hospital

Japan

Novel therapeutic approaches: current clinical trials

EDUCATION:
1996-2002 Faculty of Mdicine, Kyoto University
2005-2010 Rheumatology and Clinical Immunology, Graduate school of Medicine, Kyoto University

PROFESSIONAL TRAINING and EMPLOYMENT:
2012-Present Assistant Professor, Rheumatology and Clinical Immunology, Kyoto University Hospital
2010-2012 Clinical fellow, Rheumatology and Clinical Immunology, Kyoto University Hospital
2003-2005 Resident in Shizuoka General Hospital
2002 Resident in Kyoto University Hospital

MEMBERSHIPS:
Japan College of Rheumatology
The Japanese Society of Clinical Immunology
The Japanese Society of Inflammation and Regeneration
The Japanese Society of Internal Medicine

Shingo Nakayamada

University Of Occupational And Environmental Health

Japan

Immunophenotyping in Systemic Lupus Erythematosus

March 1996: Graduated from School of Medicine, University of Occupational and Environmental Health, Japan

June 1996: Joined the First Department of Internal Medicine, University of Occupational and Environmental Health, Japan for clinical training

March 2004: Completed doctoral program of disorder mechanism system and pathological mechanism section, Graduate School of Medical Science, University of Occupational and Environmental Health, Japan

April 2004 Assistant Professor, First Department of Internal Medicine, Hospital of the University of Occupational and Environmental Health, Japan

April 2007 Occupational Health Physician, Kobe Shipyard & Machinery Works, Mitsubishi Heavy Industries

April 2007 Part-time Researcher, Division of Cell Physiology, Department of Physiology and Cell Biology, Kobe University Graduate School of Medicine

October 2009 Visiting Fellow, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, U.S.A.

April 2012 Assistant Professor, First Department of Internal Medicine, Hospital of the University of Occupational and Environmental Health, Japan

January 2021 Associate Professor, First Department of Internal Medicine, Hospital of the University of Occupational and Environmental Health, Japan

Peter Nash

Griffith University, Brisbane

Australia

Head-to-head Study Evaluating Secukinumab versus Adalimumab in Psoriatic Arthritis Patients (EXCEED): Efficacy on ACR Components, Remission and Patient Reported Outcomes

Peter Nash is Professor in the School of Medicine at Griffith University, Queensland, and Director of the Rheumatology Research Unit on the Sunshine Coast. Prof. Nash has Chaired the Professional Affairs Committee and the Therapeutics Committee, the NHMRC musculoskeletal panels and serves on the Scientific Advisory Committee of the Australian Rheumatology Association. He is a former member of the Therapeutics Committee of the Australia and New Zealand Bone and Mineral Society. He remains on the International Steering Committee for GRAPPA. He is on the editorial board of Annals of the Rheumatic Diseases and RMD Open.

Prof. Nash and his group at the Rheumatology Research Unit have been involved with pivotal registration clinical trials for all modern targeted biologic therapies and osteoporosis therapies. He has published more than 200 peer-reviewed papers and 5 book chapters and was recently recognized as rheumatology citation leader top 20 rheumatology journals over the last 5 years. His special interests include metabolic bone disease and novel therapeutics.

Sue-Ann Ng

Singapore General Hospital

Singapore

Update on APLAR systemic sclerosis project

Dr Sue-Ann Ng is a Consultant in the Department of Rheumatology and Immunology, Singapore General Hospital. She has a keen interest in clinical and research work in systemic sclerosis.

Elena Nikiphorou

King’s College Hospital & King’s College London

United Kingdom

The use of social media among rheumatologists: reality vs perspectives

Consultant Rheumatologist at King’s College Hospital & Adjunct Senior Lecturer at King’s College London. Clinical and academic interest in inflammatory arthritis.

Babur Salim

Pakistan Society for Rheumatology(PSR)

Pakistan

Chairperson

Associate Professor of Rheumatology
Fauji Foundation Hospital Rawalpindi
Pakistan

Sakae Tanaka

The University Of Tokyo

Japan

Chairperson

Sakae Tanaka MD, PhD graduated from University of Tokyo in 1987. He learned osteoclast biology in Department of Biochemistry, Showa University School of Dentistry from 1990 to 1993 and worked as a postdoctoral associate in Department of Cell Biology, Yale University School of Medicine from 1993 to 1995. He has been serving as Professor in the Department of Orthopaedic Surgery, Faculty of Medicine, the University of Tokyo since 2012. He has more than 500 international publications, 50 international presentations in international congresses and more than 15,000 citations in indexed international scientific journals with h-index 58. His clinical specialty is joint surgery and clinical interest includes rheumatoid arthritis and osteoporosis. His scientific fields of interest are osteoclast biology, signal transduction and apoptosis.

Dennis McGonagle

United Kingdom

Pathogenesis and therapy with rheumatic drugs in COVID

Yoshiya Tanaka

University of Occupational and Environmental Health

Japan

Chairperson

Yoshiya Tanaka, MD, PhD is Professor and Chairman of the First Department of Internal Medicine, School of Medicine (2000-present) and Dean of Graduate School of Medical Science (2017-present), University of Occupational and Environmental Health, Japan. He reviewed >740 publications in English (impact factor >3600, h-index 88). His scientific focus lies on pathological mechanism and development of novel treatment in rheumatic diseases and osteoporosis. He was a president of JSBMR in 2013-15. He is a chair of scientific committee of APLAR, chair of international committee of JCR, president of JACI. He received numerous awards from JSBMR, JCR and EULAR.

Hisanori Umehara

Nagahama City Hospital

Japan

TBA

Dr. Umehara is a vise president, Nagahama City Hospital. He is a Rheumatologist with wide knowledge of Clinical and Basic Immunology. Dr. Umehara has been a professor and chairman, Kanazawa Medical University, and served as the Japanese director of Sjögren’s International Collaborative Clinical Alliance (SICCA) during 2006 to 2014, and a chairman of All Japan IgG4-RD team by Health, Labor and Welfare, Japan (2011-2013). He has published many papers on IgG4-related disease including comprehensive diagnostic criteria for IgG4-RD, 2011.

James Wei

Taiwan

Chairperson

Chris Wincup

University College London

United Kingdom

Social media for Rheumatology Practice

Having qualified from Brighton & Sussex Medical School in 2009 with MBBS and 1st Class (hons) BSc in Biomedical Sciences I began my post-graduate medical training in North West London where I was awarded an Academic Foundation Post allowing me to undertake research at the Kennedy Institute of Rheumatology (Charing Cross Hospital). I undertook Core Medical Training based at Northwick Park, Hammersmith and Charing Cross Hospitals during which I gained membership to the Royal College of Physicians.

In 2013, I began specialist post-graduate training in the field of Rheumatology and General Internal Medicine. Since October 2016 I have been working as a Clinical Research Fellow exploring abnormal iron metabolism and mitochondrial dysfunction in systemic lupus erythematosus (SLE) at University College London. I have been funded by LUPUS UK and UCLH Charity in addition to being awarded the Versus Arthritis (formerly Arthritis Research UK) Clinical Research Fellowship that is funding my PhD work. In 2018 I was awarded the Kovac’s Travelling Fellowship by the Royal Society of Medicine to spend time working at the Rheumatology Department at Northwestern Hospital, Chicago (USA) where I formed a research collaboration.

I hold membership of a number of profession organisations including acting as Rheumatology Trainee Representative to the Royal Society of Medicine. I am the British Society for Rheumatology (BSR) BRiTs representative for North Central / East London. Since 2018 I have been a member of the EULAR-EMEUNET Working Group.

Motohisa Yamamoto

The Institute of Medical Science, The University of Tokyo

Japan

Topics on advanced clinical practice for IgG4-related dacryoadenitis/sialadenitis and autoimmune pancreatitis

Dr. Motohisa Yamamoto is a rheumatologist, belonging to The Institute of Medical Science, The University of Tokyo since 2019. The theme of his research is the pathological elucidation and development of new treatments for IgG4-related disease. Until now, he has been mainly engaged in clinical research on IgG4-related disease. He contributed the separation and the independence of Mikulicz’s disease (IgG4-related dacryoadenitis and sialadenitis) from Sjögren’s syndrome. Next, He was involved in the development of the comprehensive diagnostic criteria, 2011. He and his colleagues established the registry for the patients with IgG4-related disease, a SMART registry, and they announced several important findings in clinical practices. He firstly reported that standardized incidence ratio of malignancies in IgG4-related disease was significantly increased. He now tries to challenge the omics analysis in IgG4-related disease.

Hajime Yoshifuji

Kyoto University

Japan

Genetic and immunological mechanisms of large-vessel vasculitis

Since 2000, Dr. Yoshifuji has been engaged in the treatment and research of patients with autoimmune diseases, especially Takayasu arteritis (TAK), IgG4-related disease, and relapsing polychondritis (RP) at Kyoto University. Since 2013, he has made important contributions in genomic study and clinical trials for Takayasu arteritis. He also contributed to the composition of Japanese treatment guidelines for vasculitidis revised in 2017 as the prime secretariat manager. Currently, he is an Associate Professor/Lecturer at Dept. of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University. He is dedicated to supporting two Japanese patient associations for TAK and RP.

Takako Miyamae

Tokyo Women’s Medical University

Japan

TBA

Dr. Takako Miyamae is an Associate Professor in Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University in Tokyo, Japan. She is also the president of this year’s Annual Meeting of the Pediatric Rheumatology Association of Japan.

Justin Mason

Imperial College London

United Kingdom

Imaging of large vessel vasculitis

Justin Mason was the recipient of Arthritis Research UK (ARUK) Intermediate and Senior Clinical Research Fellowships. He was appointed Professor of Vascular Rheumatology at Imperial College in 2009, Head of Vascular Sciences in 2017, Head of the Cardiovascular Division of the National Heart and Lung Institute in 2018 and Co-Director of the Imperial College Centre of Vasculitis Research Excellence in 2020. He has served as Chair of the ARUK Research and Capacity Committee and on the British Society for Rheumatology Heberden Committee. His basic science research focuses upon the relationship between vascular endothelial dysfunction and systemic inflammatory diseases, and he has a specialist clinical research interest in the investigation and management of the large vessel vasculitides including Takayasu arteritis.

Thaschawee Arkachaisri

KK Women’s and Children’s Hospital

Singapore

Cytokine targeted therapy for Pediatric Rheumatic Diseases in Singapore

Dr. Tash graduated from Mahidol University, Thailand in 1991. He then pursued his specialty and subspecialty training in the US and earned his American Board of Pediatrics, Allergy and Immunology and lastly, Pediatric Rheumatology at Cornell University prior to returning back to Thailand and established the first Pediatric Rheumatology department at Siriraj Hospital and Mahidol University in January 2001. He then moved back to the US and joined Children’s Hospital of Pittsburgh where he gained his research interest in scleroderma and established the first Pediatric Scleroderma clinical and research Program in 2006. Then, he developed the Localized Scleroderma Cutaneous Assessment Tool which is the well-accepted clinical assessment measures in Localized Scleroderma and has been well-accepted as the standard assessment worldwide.

In 2009, he then moved back to Singapore to established its first Pediatric rheumatology clinical program and in 2011, the Asia-Pacific Pediatric Rheumatology Education and Research Network. Over the decades, he has published the epidemiologic and outcomes of children with rheumatic diseases in Singapore and Southeast Asia. He also actively involved in pediatric rheumatic diseases translational researches in trying to better understand the underlying immune-mechanisms and predict outcomes. He is currently an Associate Professor, head and senior consultant at the Rheumatology and Immunology Department at KK Women’s and Children’s Hospital and Duke-NUS Medical School.

Latika Gupta

Sanjay Gandhi Postgraduate Institute Of Medical Sciences

India

Conducting research online

Dr Gupta is a rheumatologist, clinical immunologist, and clinician scientist working as Assistant Professor at SGPGI, a tertiary care teaching hospital in Lucknow, India. She currently serves as the Social Media Editor for several Rheumatology journals and is the APLAR (Asia Pacific League of Associations for Rheumatology) Young Rheumatology Webmaster and Board Member from India.

She is a dedicated researcher (136 publications, H index 12, I index 19) with an interest in myositis, spondyloarthritis and digital health. She recently founded Myositis India, a patient support group for patients with this disease.

Besides enjoying medical teaching Dr Gupta enjoys amateur photography, poetry, and photo painting.

Sang Cheol Bae

Hanyang University

South Korea

SLE genomics

Sang-Cheol Bae is a Full Professor (1993~) and Distinguished Professor (2012~) of the Hanyang University; the former Director of the Hanyang University Hospital for Rheumatic Diseases (2005-2019); Director of Hanyang University Institute for Rheumatology Research (2019~), Seoul, Korea and the elected president of 15th International Congress on SLE (2023). His illustrious career shows excellent leadership as a medical service provider as well as a clinical and translational researcher in SLE and RA.
Professor Bae acquired his MD in 1984, and subsequently a PhD in 1993, from the Hanyang University, Seoul, Korea. From 1996 to 1998, he worked as a rheumatology research fellow and instructor at the Brigham and Women’s Hospital, Harvard Medical School, Boston, USA. In 1998, he also obtained a MPH from the Harvard School of Public Health, Boston, USA.
Professor Bae’s major research interests include

Clinical epidemiology including clinimetrics, clinical trials and innovative treatment development, clinical and pharmaco-economics, and outcomes research;
Genetic epidemiology including drug discovery and repurposing;
Precision medicine, in the field of rheumatic diseases, particularly SLE and RA. He has published ~ 700 articles on these topics in national and international peer-reviewed journals.

Christine Bernal

University Of Santo Tomas

Philippines

Cytokine Targeted Therapy for Pediatric Rheumatic Diseases in the Philippines

Dr. Bernal is a pediatric rheumatologist who, after her residency training in pediatrics in the University of Santo Tomas Hospital, pursued her fellowship training in rheumatology in Baylor College of Medicine, Houston, Texas. While training abroad, she was a recipient of several prestigious awards including Drs. Ralph and Judith Feigin Resident Award of Excellence, American College of Rheumatology (ACR) outstanding fellow award and ACR Amgen Pediatric Rheumatology Research Award. Her research works on lupus, Kawasaki, polyarteritis nodosa and juvenile idiopathic arthritis has been published in international journals including Arthritis and Rheumatism, International Journal of Rheumatic Diseases and APLAR Journal of Rheumatology. She also authored a chapter on Juvenile idiopathic arthritis for Arthritis and Allied Conditions (a textbook in Rheumatology) in 2005 & a chapter on Disorders of Bones & Connective Tissues for Fundamentals of Pediatrics in 2014.

A graduate of UST Faculty of Medicine and Surgery, she now serves her alma mater as Associate Professor. At present, she is the section chief of Pediatric Rheumatology in UST Hospital and Cardinal Santos Medical Center; an active medical consultant in a number of private tertiary hospitals in Metro Manila.

Matthew Brown

King’s College London

United Kingdom

TBA

Matt Brown is a clinician-scientist who trained initially in medicine and rheumatology in Sydney, Australia before completing a Doctorate of Medicine based at University of Oxford, focusing on genetics of ankylosing spondylitis. He was appointed Professor of Musculoskeletal Sciences at University of Oxford in 2004. In 2005 Matt returned to Australia, firstly to University of Queensland, and since 2016, at Queensland University of Technology, where he was Professor and Director of Genomics. In 2013 he was elected to Fellowship of the Australian Academy of Sciences in recognition for his achievements in genetics research. In 2019 he moved to King’s College London and Guy’s and St Thomas’ Hospitals NHS Trust to direct their NIHR Biomedical Research Centre.

Philip Conaghan

University Of Leeds

United Kingdom

Update on future therapeutics in OA treatment

Professor Philip Conaghan MBBS PhD FRACP FRCP is Director of the Leeds Institute of Rheumatic and Musculoskeletal Medicine (a EULAR Centre of Excellence) at the University of Leeds and Deputy Director of the NIHR Leeds Biomedical Research Centre. His research focuses on understanding pathogenesis and developing effective therapies for common arthritis and joint problems. He is an executive member of the international outcomes group OMERACT. He has previously chaired UK NICE osteoarthritis clinical guidance, is co-editor of the Oxford Textbook of Rheumatology and has authored/co-authored over 600 publications as original research, reviews and book chapters.

Leonila Dans

St Vincent’s Hospital Sydney And University Of New South Wales

Australia

Autologous Haematopoietic Stem Cell Transplantation For Systemic Sclerosis Results In Improved Clinical Outcome Measures Including Survival

Takahisa Gono

Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine

Japan

Update on APLAR myositis project

BIOGRAPHICAL
Name: Takahisa Gono
Business Address: Department of Allergy and Rheumatology,
Nippon Medical School Graduate School of Medicine
1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, JAPAN
Business Phone: +81-3-3822-2131
Business Fax: +81-3-5814-6024
E-Mail Address: tgono@nms.ac.jp
Birth Date: October 4th,1973
Birth Place: Tokyo, Japan
Citizenship: Japan

EDUCATION and TRAINING
UNDERGRADUATE/GRADUATE:
2004, Ph.D, Shinshu University Graduate School
1992-1998, Yamanashi University, Yamanashi, Japan, M.D. 1998

APPOINTMENTS and POSITIONS
ACADEMIC:
2016-Present Associate Professor, Department of Allergy and Rheumatology, Nippon Medical
School Graduate School of Medicine
2015-2016 Associate Professor, Department of Rheumatology, Saitama Medical Center, Jichi
Medical University
2014-2015 Associate Professor, Institute of Rheumatology, Tokyo Women’s Medical University
2007-2014 Assistant Professor, Institute of Rheumatology, Tokyo Women’s Medical University
2004-2007 Assistant Professor, Third department of Internal Medicine (Rheumatology and Neurology), Shinshu University
2001-2003 Research fellow, Third department of Internal Medicine (Rheumatology and Neurology), Shinshu University

SCIENTIFIC SOCIETY:
Councilor of The Japanese College of Rheumatology
Councilor of The Japanese Society of Clinical Immunology
Editorial Board, BioMed Research International Journal

SPECIALITY CERTIFICATION
2002 The Japanese Society of Internal Medicine
2006 The Japanese Society of Neurology
2006 The Japanese College of Rheumatology

AWARD
2012 Young Investigator’s Award of the Japanese Society of Rheumatology
2013 Young Investigator’s Award of the Japanese Society of Internal Medicine

Yutaka Kawahito

Kyoto Prefectural University of Medicine

Japan

Post Marketing Surveillance and JCR guideline

Yutaka Kawahito, MD, PhD, is a professor of the Kyoto Prefectural University of Medicine and head of the Department of Inflammation and Immunology. He graduated from the Faculty of Medicine, Shimane University, and obtained his PhD from the Kyoto Prefectural University of Medicine in 1995. He was a research fellow at NIAMS of NIH from 1995 to 1998, and has been engaged in clinical and research at Kyoto Prefectural University of Medicine since 2000. He has been involved in numerous rheumatoid arthritis activities including a chairperson of a subcommittee of treatments for rheumatoid arthritis of JCR and a member of Modern Rheumatology editorial board.

Takashi Maehara

Japan

IgG4-related disease: Immunological insights into the pathogenesis

I am activity involved in research on the pathogenesis of human autoimmune disorders especially the study of the immunological and epigenetic basis of Sjogren’s syndrome, IgG4-related disease, and systemic sclerosis. We have explored the immunology and epigenetic induction of clonally expanded disease-linked CD4+ T cells and B cells in the pathogenesis of IgG4-related disease and systemic sclerosis. Clonally expanded CD4+ T cells with a killer phenotype may cause inflammatory fibrosis in a number of clinical contexts.

I completed my DDS training at Kyushu University in 2007. Then I earned my Ph.D. in Clinical Immunology at Kyushu University in 2012. And I worked on cellular and molecular immunology at Ragon Institute of MGH, MIT and Harvard from 2015 to 2018.

Currently I am Assistant Professor, Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Japan.

Mitsuhiro Kawano

Kanazawa University

Japan

IgG4-related kidney disease and IgG4-related periaortitis/retroperitoneal fibrosis

Mitsuhiro Kawano is a Japanese rheumatologist who is currently the director and associate professor of the Department of Rheumatology at Kanazawa University Hospital. He received the M.D. degree from Kanazawa University in 1987, and the Ph.D. degree in 1993. He is actively involved in routine patient care, teaching and research in rheumatology. He has been the first president of the Japanese Association of IgG4-Related Disease since September, 2019, and helped to publish the first English-language textbook on IgG4-related disease as a co-editor with Professor John H. Stone of Harvard Medical School in 2012. Recently, the ACR/EULAR IgG4-RD Classification Criteria Working Group has published international classification criteria for IgG4-related disease, and he took part in the working group as a core member.

Mitsumasa Kishimoto

Kyorin University School Of Medicine

Japan

TBA

He is currently serves as an associate professor at Kyorin University School of Medicine.

After completing the first training in Japan, he completed an Internal Medicine Residency program at the University of Hawaii, and a Rheumatology Fellowship program at New York University. In 2006 he took the role of Program Director of the Department of Rheumatology at the Kameda Medical Center, then from 2009 to 2019, clinical program director in St Lukes International hospital before moving on to accept his current positions in 2019.

Dr Kishimoto was certified by the American Board of Internal Medicine and Rheumatology and received an ACR Distinguished Fellow Award in 2006.

He was a Steering committee member in the ‘APLAR guidelines for management of rheumatoid arthritis and is currently SIG member in Spondyloarthritis. He also serves as a Steering committee member in JCR guidelines for management of RA and SpA in Japan.

He is a GRAPPA and ASAS member, and Japan’s Principal Investigators for the ‘ASAS-Comospa and perSpA’ studies.

Dr Kishimoto is an author of over 90 scientific publications including NEJM and Lancet articles.

Ichiro Kobayashi

KKR Sapporo Medical Center

Japan

Interstitial lung disease in juvenile dermatomyositis in Asia

Dr. Ichiro Kobayashi graduated from Hokkaido University School of Medicine in 1984. After 5 years of clinical training as a pediatrician, he was engaged in the study of interleukin-6 receptor at Osaka University (Prof. T. Kishimoto’s Lab), and autoantibodies particularly associated with primary immunodeficiencies such as IPEX syndrome at Hokkaido University Hospital. In parallel with laboratory works, he has published clinical articles on pediatric rheumatic diseases such as juvenile dermatomyositis and pediatric Sjogren’s syndrome. He is now working at KKR Sapporo Medical Center as a Chief Pediatrician, and at Hokkaido University as a Visiting Professor.

Masataka Kuwana

Nippon Medical School

Japan

Chairperson

Dr. Masataka Kuwana is a professor of rheumatology and a director of scleroderma/myositis center of excellence at Nippon Medical School in Tokyo, Japan. Dr. Kuwana has published more than 410 peer-reviewed scientific articles and written more than 10 book chapters. He is listed as an editorial board member of 7 peer-reviewed journals, and serves as an Editor-in-Chief of Modern Rheumatology and the Journal of Scleroderma and Related Disorders. Dr. Kuwana is considered an internationally recognized leading expert in systemic sclerosis, myositis, pulmonary hypertension, interstitial lung disease, and autoimmunity.

Vidya Limaye

Royal Adelaide Hospital

Australia

Necrotising Myopathies: Update

Vidya Limaye is a staff specialist Rheumatologist in the Department of Rheumatology at the Royal Adelaide Hospital. After completing her rheumatology training she undertook a PhD in the Vascular Biology Laboratory at the Hanson Institute studying the role of sphingosine kinase in inflammation and angiogenesis. She has since established the South Australian Myositis Database; this is a large repository of over 900 patients with myositis which has enabled the study of clinical, epidemiological and immunogenetic aspects of inflammatory myopathies. She has a particular interest in myositis-specific autoantibodies and in the increasingly recognised subgroup of patients with necrotising myopathy.

Andrea Low

Singapore General Hospital

Singapore

Microbiome in Systemic Sclerosis

Dr Andrea Low is Head and Senior Consultant in the Department of Rheumatology and Immunology, Singapore General Hospital. Her clinical and research interest is in systemic sclerosis (SSc). She spear-headed the nation-wide collaborative SSc research workgroup dedicated to advancing clinical care and research in SSc, and established the Systemic Sclerosis Cohort in Singapore (SCORE) since 2008. She is recipient of several awards including the National Medical Research Council Transition Award and Clinician Scientist Award for her work in SSc. She has garnered $3.8 million in grant funding and published extensively in this area. She is convenor of the APLAR systemic sclerosis/myositis special interest group, and member of the Scleroderma Clinical Trials Consortium.

Pedro Machado

University College London

United Kingdom

EULAR COVID-19 database and EULAR COVAX Database

Dr Pedro Machado, MD, PhD, FRCP, is an Associate Professor and Consultant Rheumatologist at University College London (UCL), University College London Hospitals (UCH) and Northwick Park Hospital, United Kingdom. He is a Principal Investigator at the UCL Centre for Rheumatology and at the UCL Department of Neuromuscular Diseases. His research interests include the assessment and prediction of outcomes in rheumatic diseases, with a focus on axial spondyloarthritis, myositis and COVID-19. He has published >155 peer-reviewed articles.

Dr Machado is the past-chair of the European Alliance of Associations for Rheumatology (EULAR) Standing Committee on Epidemiology and Health Services Research (SCEHSR). He is a member of the EULAR Research Committee, the COVID–19 Global Rheumatology Alliance (GRA) Steering Committee, the EULAR COVID-19 Registry steering group, Assessment of Spondyloarthritis International Society (ASAS), British Society of Spondyloarthritis (BRITSpA), International Myositis Assessment and Clinical Studies Group (IMACS), Muscle Study Group (MSG), British Society of Rheumatology (BSR), and the Portuguese Society of Rheumatology (SPR).

Sponsor Name

Sponsor bio – Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Industry Program Sponsor

Asahi Kasei Pharma Corporation

1735 - 1835 GMT+9Monday 30 August

Evening Symposium 6

The role of targeted therapies against interleukin-6 receptor in rheumatoid arthritis

#APLAR21

Asahi Kasei Pharma Corporation

Laila Girgis

Ying Ying Leung

Janssen Pharmaceutical KK & Mitsubishi Tanabe Pharma Corporation

CSF

Contact

Asami Abe

Ori Elkayam

David Karp

Kong Kok Ooi

Isao Matsumoto

LG Chem

Contact

Iain McInnes

CC Mok

Eric Morand

Sandra Navarra

Kenji Oku

Yohei Seto

Celltrion Healthcare

Contact

Association of Women in Rheumatology

Amita Aggarwal

Pfizer. Japan Inc

Janssen, a division of Johnson & Johnson

Eli Lilly Japan K.K.

AbbVie

Bristol Myers Squibb K.K.

Gilead Sciences K.K.

Novartis Pharma K.K.

Cesas Medical

Sales Operation Area Management Support, Japan Commercial, Astellas Pharma Inc.

Boehringer Ingelheim

Chugai Pharmaceutical Co., Ltd

Daiichi Sankyo Co., Ltd.

Glaxosmithkline

UCB Biopharma SRL

Lai-shan Tam

Yannick Allanore

Keishi Fujio

Katsuya Suzuki

Ran Nakashima

Shingo Nakayamada

Peter Nash

Sue-Ann Ng

Elena Nikiphorou

Babur Salim

Sakae Tanaka

Dennis McGonagle

Yoshiya Tanaka

Hisanori Umehara

James Wei

Chris Wincup

Motohisa Yamamoto

Hajime Yoshifuji

Takako Miyamae

Justin Mason

Thaschawee Arkachaisri

Latika Gupta

Sang Cheol Bae

Christine Bernal

Matthew Brown

Philip Conaghan

Leonila Dans

Takahisa Gono

Yutaka Kawahito

Takashi Maehara

Mitsuhiro Kawano

Mitsumasa Kishimoto

Ichiro Kobayashi

Masataka Kuwana

Vidya Limaye

Andrea Low

Pedro Machado

1735 - 1835 GMT+9
Monday 30 August